Early bird for inaugural Australia China Life Science Summit ending soon

Early bird registrations will close on 15 February for AusBiotech’s inaugural Australia China Life Science Summit.

AusBiotech’s inaugural Australia China Life Science Summit has been developed in acknowledgement of the leading role China is expected to take in the future of life sciences globally. Supported by DLA Piper, the event is designed to share knowledge and gain expert views and experiences of others who have successfully created linkages and developed partnerships in the region.

China has made a clear commitment to develop life sciences with biotechnology set as one of seven priority industries in China’s 12th Five Year Plan. Australia and China have together established a joint Science and Research Fund, and China is expected to become the second largest pharmaceutical market in the world by 2015.

Registration is now open for the event, to be held 26-27 March 2013 in Melbourne. The summit is an excellent educational and networking opportunity and will bring together key stakeholders from Australia and China to discuss China’s life science industry landscape.

The program (to date) can be found here.

Key speakers include:

• The Hon John Brumby, Former Victorian Premier, Vice-Chancellor's Professorial Fellow at the University of Melbourne and Monash University and independent Director, Huawei Technologies (China)
• Secretary William S Cohen, Chairman and CEO, The Cohen Group and Senior Advisor to DLA Piper
• Dr Mona Chung, Principal Consultant, Cross Culture Interactions (author of Shanghaied: Why Fosters could not survive China and Doing Business Successfully in China), Board Member of Australia China Business Council and Lecturer, Deakin University
• Rob Scott, Director, China BlueSky Ventures, Shanghai, China
• Ms Fatima Beattie, Deputy Director General, IP Australia
• Kit Kwok, Head of Corporate, DLA Piper Shanghai
• Sammy Fang, Head of Litigation and Regulatory, DLA Piper Beijing
• Nicholas Tyacke, Partner, Life Sciences and Intellectual Property and Technology, DLA Piper Australia
• Dr Simone Mitchell, Partner, Life Sciences and Intellectual Property and Technology, DLA Piper Australia
• David Morris, Joint Head of Corporate Asia Pacific, DLA Piper Australia
• Binhui Ni, Head of Scouting & Partnering, Sanofi Aventis, China
• Dr Jens Tampe, Deputy Director, Griffith Enterprise
• Ross Harvey, Director of Logistics Asia Pacific, Cook Medical
• Stefan R Granitzer, Senior Product Manager/Global Marketing - Implants, Surgical Products and Strategy, Cochlear Limited
• Duncan Hart LLB MBA, Duncan Hart Consulting
• Ling Jin, Partner and Head of Rouse Technology Group, China
• Jenny Petering, Partner, FB Rice
• James Hudson, East Asia Advisor, CSIRO International
• Dr Janette Dixon, Vice President Global Business Development, QRx Pharma
• Dr Julian Chick, Chief Operating Officer, Allied Healthcare Group
• Professor Andrew Wilks, Executive Chairman, SYNthesis
• Associate Professor David Anderson, Deputy Director and Head Diagnostics Development Program, Burnet Institute
• Nick Weston, Chief Executive Officer, Agenix Ltd (ASX:AGX)
• Cameron Boardman, Head of Australia and New Zealand, Invest HK
• Amanda Turnill, Chair of AusBiotech’s NSW Branch Committee; Global Co-chair and Sector Leader for Life Sciences Asia Pacific, DLA Piper Australia
• Australia China Business Council
• Australia China Association for Biomedical Sciences (ACABS)
• Representatives from big pharma

For more information and registration, visit the Australia China Life Science Summit website.

For further information on sponsorship and program opportunities, email Hayley Laing or call +61 (3) 9828 1400.